Close mobile menu×
Close mobile menu

Julia L. Glade Bender, MD

Board Certifications: 
Pediatric Hematology-Oncology, Pediatrics
Expertise in: 
Cancer Care
Accepting New Patients
Treats Children
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-9770

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Pediatric Hematology-Oncology
  • Pediatrics

Clinical Expertise

  • Cancer Care
  • Pediatric Oncology
  • Pediatric Cancer
  • Pediatric Solid Tumors
  • Metastatic Cancer
  • Neuroblastoma
  • Soft Tissue Sarcoma
  • Bone Tumors
  • Germ Cell Tumor
  • Wilm's Tumor
  • Clinical Research Trials
  • Molecular Medicine
  • Immunotherapy
  • Vascular Malformation

Specialties

Education & Training

  • University of Pennsylvania School of Medicine
  • Internship: Mount Sinai Medical Center
  • Residency: 1995 Mount Sinai Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center, NY

About Julia Glade Bender

Children's Gala 2016 - Betty & Ethan's Story

Julia Glade Bender, MD cares for children, adolescents, and young adults with solid tumors, particularly neuroblastoma, sarcoma, germ cell tumors, and other rare tumors. She has special expertise in the treatment of young patients with cancers that have become resistant (refractory) to treatment or have relapsed (come back) after therapy.

Dr. Bender is attracted to the intellectual and emotional challenges of diagnosing, understanding, and treating complex illnesses. There's much to be learned about tumor biology and the growth pathways involved in cancer that can be translated into better therapies for children. Her goal is to apply the results of her clinical experience and research to improve the care of young people with cancer, using more effective therapies with fewer side effects. For most patients, standard chemotherapy using existing anticancer drugs will continue to be the best approach. But for others, there's great hope that the newer biologic and targeted therapies being developed today may have activity against childhood cancers. Dr. Bender is also intrigued by genetics and the new sequencing technologies that allow for the exploration of the differences between tumor cells and normal cells in an individual child with cancer.

At NewYork-Presbyterian/Morgan Stanley Children's Hospital, Dr. Bender serves as medical director for the Precision in Pediatrics Sequencing (PIPseq) Program, which works to identify the molecular drivers of each patient's cancer and use this information to personalize his or her treatment using novel, biologically targeted investigational agents. She also directs the Developmental Therapeutics Program, which explores the safety and effectiveness of new cancer therapies in children with refractory disease through clinical trials. The center is the only pediatric oncology program in New York selected to participate in the Children's Oncology Group (COG) Phase I Consortium, a group of 21 institutions in the country designated by the National Cancer Institute to conduct Phase I pediatric clinical trials - the earliest phase of studies for patients. The Developmental Therapeutics Program also serves as a home for industry-sponsored and investigator-initiated trials supported by data generated by laboratory research partners. For patients with refractory or relapsed cancer who are not participating in clinical trials, Dr. Bender and her team work to assemble a combination of existing drugs that is customized to each patient's disease.

Academic Titles

  • Associate Professor of Pediatrics at CUMC

Administrative Positions

  • Associate Director, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation
  • Medical Director, Precision in Pediatrics Sequencing (PIPseq) Program
  • Medical Director, Developmental Therapeutics Program

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Morgan Stanley Children's Hospital

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-9770
Fax:
(212) 305-5848
Primary

Research

My mission is to improve cure rates for the most aggressive pediatric tumors and mitigate side effects one patient at a time.  Early phase clinical trials not only help to move the field forward but also provide children access to the newest investigational agents in development to treat cancer including inhibitors of growth pathways, modulators of cellular and molecular control mechanisms and immunotherapy. I established the Pediatric Developmental Therapeutics Program  to serve as the research home for studies sponsored by the Children’s Oncology Group (COG) Phase 1 Consortium, other consortia specific to recurrent neuroblastoma and leukemia, industry and investigator-initiated trials. I have also provided scientific leadership for over 15 early phase clinical trials sponsored by the National Cancer Institute and pharmaceutical industry and have developed an international reputation for the early pediatric development of the vascular endothelial growth factor (VEGF) neutralizing agents, bevacizumab and aflibercept, and several multi-tyrosine kinase inhibitors including sorafenib, sunitinib, and pazopanib. My ability to effectively participate in team clinical research has led to appointments to numerous prominent COG committees, including the Developmental Therapeutics, Bone Tumor, and Neuroblastoma Steering committees where I have served as the leader of the task force on post-consolidation “maintenance” therapies and new agents liaison. On a broader scale, I serve as consultant to the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) and am a member of the NCI Pediatric and Adolescent Solid Tumor Steering Committee.

Research Interests

  • Phase I clinical trials
  • Solid tumors

Clinical Trials

NCT01922076 A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas

NCT01962103 A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.

NCT02116777 A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies

NCT02164838 A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors - This study is ongoing, but not recruiting participants.

NCT02171260 This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113)

NCT02304458 A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

NCT02564198 A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

NCT02650401 A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

NCT02756845 A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection

NCT02780804 A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT02808650 A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

COMPLETED

NCT01697579 A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy Sub-title: Open-Label Cohort to Further Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients Birth to <12 Years Old</p>

Grants

SERVICE AGREEMENT - GLADE-BENDER E7080-A-001-216/ADVL1711 (P&S Industry Clinical Trial)

Apr 5 2018 - Apr 5 2023

A PHASE 1 STUDY OF PEVONEDISTAT (MLN4924, IND# 136078), A NEDD8 ACTIVATING ENZYME (NAE) INHIBITOR, IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)

Mar 28 2018 - Mar 28 2023

SERVICE AGREEMENT: REVIEW MATERIAL AND PROVIDE FEEDBACK (P&S Industry Clinical Trial)

Mar 9 2018 - Mar 9 2023

PHASE IB /II CLINICAL TRIAL OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN PEDIATRIC SUBJECTS WITH HIGH GRADE PRIMARY CNS MALIGNANCIES (P&S Industry Clinical Trial)

Aug 2 2017 - Aug 2 2022

A PHASE 1 STUDY OF LY2606368, A CHK1/2 INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS (P&S Industry Clinical Trial)

Jun 12 2017 - Jun 12 2022

A PHASE 1/1B, OPEN LABEL, DOSE ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS WIHT OR WIHTOUT TRK,ROS1 OR LAK FUSIONS (P&S Industry Clinical Trial)

Jun 9 2017 - Jun 9 2022

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Dec 31 2019

2017 HYUNDAI HOPE ON WHEELS YOUNG INVESTIGATOR GRANT (Private)

Dec 31 2017 - Dec 30 2019

A PHASE 1/2 STUDY OF PF-02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CELL LYMPHOMA (P&S Industry Clinical Trial)

Oct 6 2014 - Oct 31 2019

ADVL1315 A PHASE 1 STUDY OF THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR AXITINIB (INLYTA, IND# 123101) IN CHILDREN WITH RECURRENT OR REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)

Oct 13 2014 - Oct 13 2019

A PHASE 1 STUDY OF ERIBULIN MESYLATE (E7389, IND #116,292), A NOVEL MICROTUBULE TARGETING CHEMOTHERAPEUTIC AGENT IN CHILDREN WITH REFRACTORY OR RECURRENT SOLID TUMORS (EXCLUDING CNS), INCLUDING LYMPHOMAS (P&S Industry Clinical Trial)

Aug 12 2014 - Aug 12 2019

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2019

A PHASE 1/2, MULTICENTER, OPEN LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF WEEKLY NAB-PACLITAXEL IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)

Jun 11 2014 - Jun 11 2019

A PHASE 1 STUDY OF THE TEM-1 ANTIBODY, MORAB-004 (IND# 103821), IN CHILDREN WITH RECURRENT OR REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)

Mar 19 2014 - Mar 19 2019

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Dec 31 2018

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Dec 31 2018

COLUMBIA UNIVERSITY DEVELOPMENTAL THERAPEUTICS PROGRAM: STRIVING FOR EXCELLENCE (Private)

Jan 1 2014 - Dec 31 2018

PRECISION MEDICINE PROGRAM FOR CHILDREN WITH HIGH-RISK CANCERS (Private)

Jan 1 2016 - Sep 30 2018

SUPPORT, NIH COG PHASE 1 GRANT (Federal Gov)

Aug 1 2014 - Sep 30 2018

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2018

A PHASE IIB, PARTIALLY-BLINDED, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF FOSAPREPITANT IN PEDIATRIC PATIENTS FOR THE PREVENTION OF (P&S Industry Clinical Trial)

Apr 24 2013 - Apr 30 2018

A PHASE 1 TRIAL OF NECTAR (NELARABINE, ETOPOSIDE AND CYCLOPHOSPHAMIDE IN T-ALL RELAPSE): A JOINT STUDY OF TACL AND POETIC (P&S Industry Clinical Trial)

Mar 1 2013 - Mar 1 2018

MATCH COMMITTEE NIH NATIONAL CLINICAL TRIALS NETWORK (NCTN) GRANT (U10CA180886 (Federal Gov)

Mar 1 2017 - Feb 28 2018

MULTICENTER COHORT STUDY TO EVALUATE OUTCOMES AFTER RECEIPT OF TARGETED THERAPY MATCHED TO AN INDIVIDUALIZED CANCER THERAPY (ICAT) RECOMMENDATION IN CHILDREN AND YOUNG ADULTS WITH RECURRENT, REFRACTOR (Private)

Oct 1 2016 - Sep 30 2017

RELAPSED CHILDHOOD NEUROBLASTOMA AS A MODEL FOR PARENTAL END-OF-LIFE DECISION MAKING (Private)

Jul 13 2015 - Jul 12 2017

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2017

SOHN COLLABORATIVE FOR PEDIATRIC CANCER RESEARCH (Private)

Apr 22 2014 - Dec 31 2016

SUPPORT, NIH COG PHASE 1 GRANT (Federal Gov)

Aug 1 2014 - Jul 31 2016

PER CASE REIMBURSEMENT AND PATIENT STUDIES (Federal Gov)

Aug 1 2014 - Jul 31 2016

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2016

COOKIES FOR KIDS CANCER SUPPLEMENTAL REIMBURSEMENT (Private)

Jun 1 2015 - May 31 2016

SOHN COLLABORATIVE FOR PEDIATRIC CANCER RESEARCH (Private)

Apr 22 2014 - Apr 21 2016

PHASE 2 STUDY OF VINCRISTINE VS SIROLIMUS FOR THE TREATMENT OF HIGH RISK KAPOSIFORM HEMANGIOENDOTGHELIOMA (Federal Gov)

Sep 10 2014 - Aug 31 2015

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2015

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2014

REPLAPSED CHILDHOOD NEUROBLASTOMA AS A MODEL FOR PARENTAL END-OF-LIFE DECISION-MAKING (Private)

May 1 2013 - Apr 30 2014

A PILOT STUDY OF DECITABINE AND VORINOSTAT WITH CHEMTHERAPY FOR RELAPSED ALL (Federal Gov)

Feb 26 2013 - Feb 25 2014

STUDY OF AC220 FOR CHILDREN WITH RELAPSED OR REFRACTORY ALL OR AML (Private)

Feb 22 2013 - Feb 21 2014

CHILDREN S ONCOLOGY GROUP CCOP (Federal Gov)

Aug 1 2007 - Jul 31 2013

PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)

Jul 1 2005 - Jun 30 2013

COG MASTER FOR NON-INDUSTRY STUDIES (Federal Gov)

Mar 1 2012 - Feb 28 2013

CHILDREN S ONCOLOGY GROUP CHAIR S GRANT (Federal Gov)

Aug 1 2009 - Jul 31 2012

CHILDREN''S ONCOLOGY GROUP CHAIR''S GRANT (Federal Gov)

Aug 1 2009 - Jul 31 2012

CHILDREN''S ONCOLOGY GROUP- CCOP (Federal Gov)

Aug 1 2007 - Jul 31 2012

CHILDREN''S ONCOLOGY GROUP- CCOP (Federal Gov)

Aug 1 2007 - Jul 31 2012

CHILDREN''S ONCOLOGY GROUP- CCOP (Federal Gov)

Aug 1 2007 - Jul 31 2012

CHILDREN''S ONCOLOGY GROUP- CCOP (Federal Gov)

Aug 1 2007 - Jul 31 2012

CHILDREN''S ONCOLOGY GROUP- CCOP (Federal Gov)

Aug 1 2007 - Jul 31 2012

A NEW YORK BASED PEDIATRIC ONCOLOGY DEVELOPMENTAL THERAPEUTI CS PROGRAM (Private)

Jul 1 2010 - Jun 30 2012

NANT CONSORTIUM (Federal Gov)

Jun 1 2010 - May 31 2012

ARRA CLINICAL STUDY FUNDING RIDER PHASE I EXPERIMENTAL THERA PEUTICS PROGRAM SUBCONTRACT (Federal Gov)

Jun 1 2009 - May 31 2012

CHILDREN''S ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (Federal Gov)

Jun 1 2009 - May 31 2012

A NEW YORK BASED PEDIATRIC ONCOLOGY DEVELOPMENTAL THERAPEUTI CS PROGRAM (Private)

Jul 1 2008 - Jun 30 2010

A PILOT STUDY INVESTIGATING THE EFFECTS OF GLUTAMINE AND VINCRISTINE-INDUCED NEUROPATHY IN PEDIATRIC PATIENTS... (Private)

Apr 1 2004 - Mar 31 2007

RELATIONSHIP OF VASCULAR REMODELING TO VEGF AND PARALLEL PROANGENIOGENIC CYTOKINE EXPESSION IN PEDIATRIC SOLID TUMORS (Federal Gov)

Apr 1 2004 - Mar 31 2005

Selected Publications

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print].

Tannenbaum-Dvir S, Glade-Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene 1 EML4-NTRK3 in an aggressive case of congenital fibrosarcoma. Cold Spring Harbor Molecular Case Studies. 2015: a000471.

Oberg JA, Glade Bender J, Cohn EG, Morris MC, Ruiz J, Chung WK, Applebaum PS, Kung AL, Levine JM. Overcoming Challenges to Meaningful Informed Consent for Whole Genome Sequencing in Pediatric Cancer Research. Pediatric Blood and Cancer, Pediatr Blood Cancer. 2015 Aug;62(8):1374-80. [Epub 2015 Apr 1; PMID:25832998].

Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium. Pediatr Blood Cancer. Pediatr Blood Cancer. 2015 Jan;62(1):45-51. [Epub 2014 Sep 24; PMID:25257751].

Glade Bender J, Lee A, Reid JM, Baruchel S, Roberts T, Voss S, Wu B, Ahern C, Ingle AM, Harris P, Weigel B, Blaney SM. A Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children with Refractory Solid Tumors including Soft Tissue Sarcoma: A Children’s Oncology Group Phase I Consortium Report. J Clin Oncol. 2013 Aug 20;31(24):3034-3043. [Epub 2013 Jul 15; PMID: 23857966].

Glade Bender J, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR.  A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2012 Sep 15;18(18):5081-9. [PMID: 22791883].

Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM,  Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405[PMID: 18202416].